Live Breaking News & Updates on Dsenthil Damodaran

Stay updated with breaking news from Dsenthil damodaran. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Sermonix to Host KOL Fireside Chat on Advancements in the Metastatic Breast Cancer Treatment Landscape on April 22, 2024

COLUMBUS, Ohio, April 19, 2024 (GLOBE NEWSWIRE) Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC) ....

Dana Farber Cancer Institute , United States , Dsenthil Damodaran , Simon Jenkins , Paul Plourde , Elizabeth Attias , David Portman , Barry Komm , Miriam Portman , Harvard Medical School , Parke Davis Pharmaceuticals , University Of Miami , Sermonix Pharmaceuticals Inc , Phd Md Anderson Cancer Center , Hospital Cancer Center , Phd Harvard Medical School , Cornell University , American Society Of Clinical Oncology , Md Anderson Cancer Center , Pharmaceuticals Inc , Cancer Center , Seth Wander , Massachusetts General Hospital , Evaluating Lasofoxifene , Investigational Cancer Therapeutics , American Society ,

Combination Shows Promise in Metastatic ESR1-Mutant Breast Cancer

Durable responses with lasofoxifene plus abemaciclib in post-CDK4/6 inhibitor setting ....

United States , Mayo Clinic In Rochester , Matthew Goetz , Dsenthil Damodaran , Charles Bankhead , University Of Texas Md Anderson Cancer Center , Harvard Medical School , Cancer Center , Mayo Clinic , Seth Wander , Massachusetts General Hospital , Medpage Today ,

ESR1 Coalteration Treatment Resistance Does Not Impact Lasofoxifene/Abemaciclib Efficacy in ESR1+ Metastatic Breast Cancer

The presence of ESR1 coabnormalities, including TP53 and PIK3CA mutations, and CCND1 and FGFR1 amplification, did not demonstrate a negative impact on the efficacy with lasofoxifene and abemaciclib in patients with estrogen receptor–positive, ESR1-mutant metastatic breast cancer.
....

San Antonio , United States , Dsenthil Damodaran , University Of Texas Md Anderson Cancer Center , Antonio Breast Cancer Symposium , Cancer Center , Metastatic Breast Cancer , Breast Cancer , San Antonio Breast Cancer Symposium , Phase 2 Elaine Study , Esr1 Coalteration , Tp53 And Pik3ca , Estrogen Receptor Positive ,

Dr Damodaran on Futibatinib Plus Fulvestrant in FGFR1-Amplified HR+/HER2– Breast Cancer

Senthil Damodaran, MD, PhD, discusses the efficacy of futibatinib plus fulvestrant in patients with FGFR1-amplified metastatic hormone receptor–positive, HER2-negative breast cancer according to findings from the phase 2 FOENIX-MBC2 trial. ....

United States , San Antonio , Dsenthil Damodaran , Department Of Breast Medical Oncology , University Of Texas Md Anderson Cancer Center , Division Of Cancer Medicine , Breast Medical Oncology , Cancer Medicine , Cancer Center , Antonio Breast Cancer , Patients With Estrogen Receptor Positive , Er2 Negative Metastatic Breast Cancer Harboring Esr1 Mutations , The University Of Texas Md Anderson Cancer Center , Fgfr1 Amplification , Foenix Mbc2 ,

SABCS: New Targeted Treatments Show Promise for Metastatic HR+/HER2- Breast Cancer

SABCS: New Targeted Treatments Show Promise for Metastatic HR+/HER2- Breast Cancer
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United States , Sarina Piha Paul , Dsenthil Damodaran , Transthera Bio , Transthera Sciences Nanjing Inc , Taiho Oncology Inc , University Of Texas Md Anderson Cancer Center , National Cancer Institute , Cancer Center , Antonio Breast Cancer Symposium , Breast Medical Oncology , Investigational Cancer Therapeutics , Taiho Oncology , Transthera Sciences ,